Prednisone
Active ingredient · 2 therapeutic classes
Sold as WINPRED
- Drug class
- Corticosteroids Acting Locally
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 34
- FDA reports (12 mo)
- 29,707
Overview
Plain-language summary, compiled from the cited regulatory records
Prednisone is a corticosteroid medication [1]. It belongs to the drug class of locally acting corticosteroids [1].
Prednisone is approved for use in several conditions. These include endocrine disorders such as primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis [1]. It is also indicated for rheumatic disorders as adjunctive therapy [1].
In the past 12 months, there have been 29,707 adverse event reports for prednisone [2]. Common reasons cited in these reports include off-label use, the drug being ineffective, fatigue, aggravation of a condition, and dyspnea [2]. Prednisone is available under multiple brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 29 | May 29, 2026 |
| CA Canada | Health Canada | 5 | March 18, 2026 |
USUnited States· FDA
29 products
Uses
INDICATIONS
Prednisone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2.
Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3.
Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5.
CACanada· Health Canada
5 products
Uses
APO-PREDNISONE (prednisone) is indicated for: • Adrenocortical function abnormalities: Chronic primary adrenocortical insufficiency (Addison's disease) together with mineralocorticoid or sodium supplementation; secondary adrenocortical insufficiency; adrenogenital syndrome (congenital adrenal hyperplasia).
• Allergic Disorders: Drug-induced allergic reactions; adjunct treatment in anaphylactic or anaphylactoid reactions; adjunct treatment in angioedema; severe allergic, perennial or seasonal rhinitis; serum sickness. • Collagen Disorders: Maintenance therapy in selected cases of acute rheumatic carditis; systemic dermatomyositis in children; systemic lupus erythematosus.
• Dermatologic Disorders: Atopic dermatitis; contact dermatitis; exfoliative dermatitis; bullous herpetiformis dermatitis; severe multiforme erythema (Stevens-Johnson syndrome); mycosis fungoides; pemphigus; severe psoriasis. • Gastrointestinal disorders: Inflammatory bowel disease; regional enteritis (Crohn's disease).
Drug interactions
Known interactions involving Prednisone. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 0060b86b-0b79-4c… · revised August 31, 2023 [PDF]
- [2]Health Canada (DPD) · 00312770 · revised March 18, 2026
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.